Chief Physician, Department of Medical Urologic Oncology, Doctor of Medicine from Peking University Health Science Center.
2022: Tibetan‑aid Director, Department of Nephrology, Lhasa People's Hospital, Xizang Autonomous Region
2024: Academic Director, Biotherapy Center, Yunnan Cancer Hospital
Specialties: Comprehensive therapies including chemotherapy, targeted therapy and immunotherapy for renal cell carcinoma, bladder cancer, prostate cancer and melanoma.
Representative Achievements:
As a principal sub‑investigator, he has undertaken multiple Phase I‑III clinical trials for urologic tumors and melanoma. As a principal sub‑investigator, he completed marketing or pivotal trials for new agents including toripalimab, disitamab vedotin and vorolanib. He also participated in global multicenter Phase III studies such as Sacituzumab Govitecan as a principal sub‑investigator.
He has published several SCI papers as first author or co‑first author in journals including Annals of Oncology, Journal of Clinical Oncology, Journal of Hematology & Oncology, MED and EBioMedicine. He has presided over an institutional research project on combined targeted‑immunotherapy for advanced collecting duct carcinoma, and a Natural Science Foundation project of Xizang Autonomous Region focusing on hypoxia‑related pathways and therapeutic research in bladder cancer.
English